Company Performance Metrics
- Nareg Sagherian: Vice President, Global Head of Investor Relations and Corporate Communications
- David Moatazedi: President and CEOPast Role: Allergan, Senior Vice President of Medical Aesthetics
Evolus medical aesthetics company focused on providing physicians and their patients with expanded choices in aesthetic procedures and treatments. They focus on the self-pay aesthetic market and their first product candidate, PrabotulinumtoxinA (DWP-450), is an injectable 900 kDa botulinum toxin type A complex designed to address the needs of the
large and growing facial aesthetics market. They believe they will offer physicians and patients a compelling value proposition with DWP-450.
Currently, onabotulinumtoxinA (BOTOX) is the neurotoxin market leader and the only known approved 900 kDa botulinum toxin type A complex in the United States. They believe aesthetic physicians generally prefer the performance characteristics of the complete 900 kDa neurotoxin complex and are accustomed to injecting this formulation. We have completed the clinical development program for DWP-450 for the treatment of moderate to severe glabellar lines ("frown lines") between the eyebrows in the US, EU, and Canada. The FDA issued a PDUFA date of May 15, 2018, for completion of its review of our BLA. We submitted an MAA to the EMA and a decision is expected by the second half of 2018. They have also submitted an NDS in Canada. They have an exclusive distribution license to DWP-450 from Daewoong Pharmaceuticals Co.
